Compare MakeMyTrip Ltd (MMYT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Zimmer Biomet Holdings Inc — how do they compare? MakeMyTrip Ltd trades at $44.73 (market cap $4.09B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.1× MakeMyTrip Ltd's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MMYT | ZBH | |
|---|---|---|
Market Cap | $4.09B | $16.95B |
Volume | 1,828,010 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $94.43 | $103.98 |
52-Week Low | $36.30 | $79.58 |
Typical Hold Time | 12 Days | 89 Days |
Enterprise Value | $4.75B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMYT trades at $44.73, up 3.04% today, but technical indicators signal a bearish trend with support at $42. The stock shows mixed earnings, missing Q4 2025 and Q2 2026 estimates but beating Q1 2026. Revenue grew to $978.34M in 2025, though net income margin is thin at 3.23%. Analyst consensus is strongly bullish with a $77 price target, but cash flow turned negative in 2026, and debt-to-asset ratio surged, raising financial stability concerns.
The outlook is bifurcated: strong analyst support and a high target suggest upside, but deteriorating cash flow, rising leverage, and bearish technicals pose significant risks. Investors should weigh the potential from operational resilience and a planned Indian listing against financial volatility and macroeconomic pressures on travel demand.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
